, July 1
/PRNewswire/ -- SpineSmith Partners and Celling Technologies hired Brian Burkinshaw
as Vice President of Research and Development, strengthening the company's position as an industry leader in adult stem cell technology innovations.
Burkinshaw will lead SpineSmith's product development efforts through the collaboration of the company's mechanical engineering department and Celling Technologies' team of scientists. These teams work closely with surgeons to develop unique products for the evolving market of regenerative medicine. Burkinshaw has over 30 years of experience in multiple medical device markets as a design engineer and in senior executive positions. Burkinshaw's experience includes the evaluation and development of technologies for venture capital investment, medical device design and development, project management, business development, product commercialization, patent prosecution, and operations. The company believes that the emerging field of regenerative medicine will change the landscape of medicine and require thought leaders capable of developing therapies and devices. Burkinshaw's background with both traditional orthopedic companies and emerging biologic companies provides the creative foundation to merge the fields.
"Brian is a natural leader and brings a range of experiences to the company, all of which will reinforce our position as an innovator in adult stem cell technologies," said Mike Gluk, Chief Operating Officer of SpineSmith. "Brian's market knowledge and sense of innovation will enhance our collaborative approach to the development of devices and therapies."
Burkinshaw joins a recently recruited team of seasoned medical professionals that will guide SpineSmith and Celling Technologies through the next phase of growth of their newest product portfolio: Autologous Regenerative Therapies of the 21st Century (ART-21). Mike Gluk (CFO/COO),Dr. Jim Poser (VP of Regenerative Medicine), Kevin Were (VP of Business Development) and Laura LeBoeuf (VP of Quality & Regulatory Affairs) collectively provide the experience and talent to research and develop opportunities in the field of regenerative medicine. Together the team will work on scientific research, product development and regulatory approvals that will deliver cost-effective applications and devices focused on point-of-care adult stem cell therapies across many disciplines.
The companies will launch two new innovative products in the coming months with a focus on regenerative medicine.
"I believe the future of medicine will rely heavily on biologics and the focus of these companies is to research and develop those opportunities. The scientific team at Celling Technologies provides a unique and timely foundation for product development through the research of adult autologous stem cells and their potential applications in spine, orthopedics, trauma, plastics and related disorders," said Burkinshaw.
About SpineSmith Partners, LP
SpineSmith Partners, LP designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. SpineSmith takes a different approach from other companies, utilizing a collaborative approach between scientists, engineers and spine surgeons. It's this unique approach that gives spine surgeons the ability to directly impact the direction of their product portfolio, ensuring applicability and achieving the highest standards of patient care.
Founded in Austin, Texas, in 2006, SpineSmith originated as a think tank to enable surgeon investors to have direct input into the design and distribution of spine technology. www.spinesmithusa.com
About Celling Technologies
Celling Technologies, a SpineSmith Partners company, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine. Celling Technologies' product offering focuses on autologous adult stem cell therapy and the devices and services that complement these procedures. www.cellingtechnologies.com
SOURCE Celling Technologies; SpineSmith Partners, LP